Core Viewpoint - The report from Jefferies indicates that Innovent Biologics (01801) is expanding its commercialization capabilities beyond oncology, with a focus on diverse channels and the initiation of a global Phase III clinical trial for its self-developed PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 targeting squamous non-small cell lung cancer [1] Group 1: Company Developments - Innovent Biologics is set to independently launch a global Phase III clinical trial for IBI363, which shows potential at a low dose of 1mg/kg for melanoma (mucosal and acral types) [1] - The company is undergoing a new drug application review for IBI112 (IL-23p19) for psoriasis, with expectations for approval in China in the second half of 2025 [1] Group 2: Financial Projections - Jefferies estimates Innovent Biologics' sales for the fiscal years 2025 and 2026 to be RMB 5 billion and RMB 12 billion, respectively, with a monthly average cost of RMB 1,200, comparable to semaglutide and 30% cheaper than tirzepatide [1] - The revenue forecasts for Innovent Biologics have been raised to RMB 13 billion, RMB 15 billion, and RMB 20 billion for the fiscal years 2025 to 2027 [1] Group 3: Investment Rating - Jefferies maintains a "Buy" rating for Innovent Biologics, raising the target price to HKD 105 [1]

Core Insights - Zhao Bei, known as the "Queen of ICBC Credit Suisse," manages funds totaling 16.428 billion yuan, with a significant focus on healthcare and innovative medical sectors [1] - The ICBC Frontier Medical Fund reported a net value growth rate of 15.58% for its A shares and 15.26% for its C shares, significantly outperforming the benchmark return of 2.17% [1] - The fund's top holdings include major pharmaceutical companies, with a notable shift in the portfolio as Rongchang Biopharmaceutical entered the top ten holdings while Yuyue Medical exited [1] Fund Performance - The ICBC Growth Selected Mixed Fund A shares achieved a net value growth rate of 34.63%, while C shares recorded a growth rate of 34.23%, both exceeding the benchmark return of 4.06% [3] - The fund's strategy involved increasing positions in innovative drug companies with strong R&D capabilities and potential for international expansion, while reducing exposure to small-cap innovative drug companies with excessive valuations [4] Portfolio Adjustments - In the second quarter, Zhao Bei increased holdings in pharmaceutical stocks such as Kelun Pharmaceutical, Haizhi Pharmaceutical, and East China Pharmaceutical, while reducing positions in companies like Xinlitai and Zaiqi Pharmaceutical [2][4] - The top ten holdings of the ICBC Growth Selected Mixed Fund include companies like Xinda Biopharmaceutical, Xinlitai, and Zaiqi Pharmaceutical, reflecting a strategic shift towards companies with strong growth potential [4] Market Outlook - The report indicates a positive outlook for the medical device sector, with expectations of a turning point beginning in the second half of 2025 [4] - The innovative drug sector is transitioning from an expectation-driven phase to one focused on actual orders, supported by favorable national policies [4]

Core Viewpoint - The innovative drug sector is experiencing strong performance due to favorable policies and positive earnings reports, with significant gains in Hong Kong-listed innovative drug stocks [1][2]. Policy Aspects - The National Healthcare Security Administration has introduced a "newly listed drug initial pricing mechanism" to encourage drug research and innovation, marking the first public announcement of this mechanism since last year's consultation [1]. - The mechanism aims to ensure that high-level innovative drugs can achieve returns that correspond to their high investment and risk during the initial listing period [1]. Performance Aspects - In the first half of this year, among 80 listed companies in the innovative drug sector, 34 companies reported year-on-year growth in net profit attributable to shareholders, excluding companies that turned losses into profits or reduced losses [2]. - For instance, Heng Rui Medicine achieved revenue of 15.76 billion yuan, a year-on-year increase of 15.88%, and a net profit of 4.45 billion yuan, up 29.67% [2]. - In the medical device sector, United Imaging Healthcare reported revenue of 6.02 billion yuan, a 12.79% increase, and a net profit of 998 million yuan, up 5.03% [2]. - The continuous optimization of the medical insurance catalog adjustment mechanism by the government has stimulated companies' enthusiasm for innovation, as they see increased chances of their products entering insurance and commercial insurance catalogs [2].

Core Viewpoint - The company achieved rapid revenue growth in the first half of 2025, turning a profit and exceeding market expectations [1] Financial Performance - In the first half of 2025, the company reported total revenue of 5.95 billion yuan, a year-on-year increase of 50.6% [1] - The company's IFRS profit improved significantly to 830 million yuan, compared to a loss of 390 million yuan in the same period of 2024, an increase of 1.23 billion yuan [1] - Non-IFRS profit also showed significant improvement, reaching 1.21 billion yuan, up from a loss of 160 million yuan in 2024 [1] - The gross profit margin for the first half of 2025 was 86.0%, up 3.1 percentage points from 82.9% in the previous year [2] - Research and development expenses were 1.009 billion yuan, a decrease of 391 million yuan compared to the previous year [2] - As of July 31, the company had approximately 2 billion USD in cash, indicating a strong financial position [2] Product Development and Clinical Trials - The new generation IO drug IBI363 is advancing rapidly in clinical trials, with a global Phase III trial for squamous non-small cell lung cancer already initiated [2] - The company has also started key clinical studies for IO treatment of melanoma and is preparing for a Phase III trial for third-line CRC [2] - Clinical data presented at the ASCO conference showed excellent efficacy for IBI363 in non-small cell lung cancer, melanoma, and colorectal cancer [3] - The company has expanded its commercialized products to 16, making it the Chinese company with the most approved monoclonal antibody products [3] Commercialization and Market Expansion - The PCSK9 monoclonal antibody has entered the national medical insurance directory, leading to rapid market penetration [4] - The company’s product for thyroid eye disease has achieved stable commercialization, providing new treatment options for patients [4] - The metabolic pipeline product, Ma Shidu, received approval for weight loss indications, with ongoing high-efficiency commercialization efforts [5] - A strategic partnership with Alibaba Health aims to create a comprehensive health management solution for overweight or obese individuals [5] Revenue Forecast and Investment Recommendations - The company is expected to generate revenues of 11.806 billion yuan, 15.382 billion yuan, and 21.092 billion yuan from 2025 to 2027 [5] - A DCF valuation suggests a reasonable market capitalization of 221.5 billion HKD, with a target price of 129.61 HKD, maintaining a "buy" rating [5]

Core Insights - The company achieved significant revenue growth in the first half of 2025, with total revenue reaching 5.953 billion yuan, a year-on-year increase of 50.6% [1] - The company expects to have 20 commercialized products by 2027, targeting total revenue of 20 billion yuan [1] Financial Performance - Total revenue for H1 2025 was 5.953 billion yuan, with product revenue at 5.234 billion yuan, reflecting a year-on-year increase of 37.3% [1] - NON-IFRS net profit was 1.213 billion yuan, with an EBITDA of 1.413 billion yuan and a gross margin of 86.8%, up 2.7% year-on-year [1] - Cash on hand was approximately 14.6 billion yuan as of July 31, 2025, with R&D investment amounting to 903 million yuan [1] Product Development and Pipeline - The company has a total of 16 commercialized products and 21 in the clinical pipeline [1] - In H1 2025, three oncology products were approved, including a ROS1 inhibitor and a third-generation EGFR TKI [1] - Two products in the comprehensive field were approved, including a treatment for thyroid eye disease and a dual-target weight loss drug [1] Global Strategy and Collaborations - The company is accelerating pipeline development through a global strategy, with a focus on late-stage clinical trials [1] - A global multi-center Phase III trial for IBI363 targeting tumor immune resistance is about to start [1] - Collaboration with Roche for IBI3009 has resulted in an upfront payment of 80 million USD, with potential milestone payments and sales royalties [1]

Market Overview - On September 1, the Hang Seng Index rose by 2.15%, closing at 25,617.42 points, with a total net inflow of southbound funds through the Stock Connect amounting to HKD 11.942 billion [1][3] - The total trading volume for the Stock Connect on the same day was HKD 200.589 billion, with a net buying amount of HKD 11.942 billion [1][3] Stock Performance - In the Shanghai Stock Connect, the trading volume was HKD 118.631 billion, with a net buying of HKD 5.659 billion; in the Shenzhen Stock Connect, the trading volume was HKD 81.958 billion, with a net buying of HKD 6.283 billion [1][3] - Alibaba-W was the most actively traded stock, with a trading volume of HKD 16.03349 billion and a net buying amount of HKD 0.85129 billion, closing with an increase of 18.50% [2][3] - Other notable stocks included SMIC and Huahong Semiconductor, with trading volumes of HKD 6.336 billion and HKD 4.042 billion, respectively [1][2] Net Buying and Selling - In terms of net buying, Alibaba-W led with HKD 4.069 billion, while the stock with the highest net selling was Pop Mart, with a net selling of HKD 0.722 billion, closing down by 4.34% [2][3] - The top ten actively traded stocks in the Shenzhen Stock Connect also featured Alibaba-W, SMIC, and Xiaomi Group, with respective trading volumes of HKD 12.2701 billion, HKD 4.271 billion, and HKD 2.498 billion [2][3]

Group 1 - The Hang Seng Index rose by 2.15% on September 1, with southbound trading totaling HKD 200.59 billion, including HKD 106.27 billion in buying and HKD 94.32 billion in selling, resulting in a net buying amount of HKD 11.94 billion [1] - The southbound trading through the Shenzhen Stock Connect had a total trading amount of HKD 81.96 billion, with net buying of HKD 6.28 billion, while the Shanghai Stock Connect had a total trading amount of HKD 118.63 billion, with net buying of HKD 5.66 billion [1] - Alibaba-W was the most actively traded stock with a total trading amount of HKD 28.30 billion and a net buying amount of HKD 4.92 billion, closing with an increase of 18.50% [1][2] Group 2 - Among the stocks listed, Alibaba-W, Tencent Holdings, and Huahong Semiconductor were among the top active stocks in both Shenzhen and Shanghai southbound trading, with Alibaba-W having a net buying amount of HKD 4.92 billion and Tencent Holdings at HKD 0.12 billion [2] - There were two stocks that received net buying from southbound funds for more than three consecutive days, with Alibaba-W leading at a total net buying of HKD 10.90 billion over seven days, followed by Huahong Semiconductor with HKD 1.09 billion over five days [2] - The trading data for September 1 shows that Xiaomi Group-W had a total trading amount of HKD 51.01 billion with a net selling of HKD 1.03 billion, while Pop Mart had a total trading amount of HKD 33.93 billion with a net selling of HKD 0.91 billion [2]

Group 1 - The Hong Kong Innovative Drug ETF (159567) closed with a gain of 2.67% on September 1, with a trading volume of 1.985 billion yuan [1] - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1] - As of August 29, 2024, the fund's latest share count was 6.686 billion, with a total size of 6.403 billion yuan, reflecting a year-to-date increase of 1591.03% in shares and 1594.74% in size compared to the end of 2023 [1] Group 2 - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 91.54% during the tenure [2] - The top holdings of the fund include companies such as Innovent Biologics, WuXi Biologics, BeiGene, and others, with significant weightings in the portfolio [2] - The fund's liquidity is strong, with a cumulative trading amount of 34.181 billion yuan over the last 20 trading days, averaging 1.709 billion yuan per day [1]

| 公司名称 | 成交金额 | 净买入额 | | --- | --- | --- | | 阿里巴巴-W(09988) | 160.33 亿元 | +8.51 亿元 | | 中芯国际(00981) | 63.36 亿元 | +6.32 亿元 | | 华虹半导体(01347) | 40.42 亿元 | +3.27 亿元 | | 美团-W(03690) | 35.82 亿元 | -4.73 亿元 | | 晶泰控股(02228) | 28.99 亿元 | -8104.37 万元 | | 腾讯控股(00700) | 28.35 亿元 | +5.88 亿元 | | 小米集团-W(01810) | 26.03 亿元 | -8.40 亿元 | | 泡泡玛特(09992) | 17.24 亿元 | -1.90 亿元 | | 比亚迪股份(01211) | 16.30 亿元 | +8.09 亿元 | | 美图公司(01357) | 16.17 亿元 | +4.57 亿元 | 深港通（南向）十大活跃成交公司 | 公司名称 | 成交金额 | 净买入额 | | --- | --- | --- | | 阿里巴巴-W(09988) | 12 ...

Core Viewpoint - Credit Suisse has raised its sales forecasts for Innovent Biologics (01801) for this year, next year, and 2027 by 2.7%, 0.8%, and 2.8% respectively, while also increasing net profit forecasts by 90.4%, 25.3%, and 25.3% for the same years, with a target price adjustment from HKD 108.4 to HKD 111.4, maintaining an "outperform" rating [1] Group 1 - Innovent Biologics reported a strong mid-year performance, with sales increasing by 50.6% year-on-year and achieving a net profit of RMB 834 million, exceeding expectations [1] - The approval of GLP-1 dual agonists and the upcoming launch of IL-23 are expected to further drive profitability growth for Innovent Biologics [1] - The highly anticipated PD-1/IL-2 drug IBI363 is ready for a global MRCT trial targeting I/O recurrent squamous non-small cell lung cancer, while the CLDN18.2 ADC is undergoing a second MRCT trial for pancreatic cancer [1]